Resistance Training in Lung Cancer Patients on Chemotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kristina Karvinen, East Carolina University
ClinicalTrials.gov Identifier:
NCT01130714
First received: January 6, 2010
Last updated: July 12, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.


Condition Intervention
Inflammation
Lung Cancer
Behavioral: Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy

Resource links provided by NLM:


Further study details as provided by East Carolina University:

Primary Outcome Measures:
  • Systemic inflammation measured by c-reactive protein. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Chemotherapy completion [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: January 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Resistance training
Group assigned to complete resistance training during duration of chemotherapy.
Behavioral: Exercise
Resistance training with resistance bands.
No Intervention: Control
Usual care.
Behavioral: Exercise
Resistance training with resistance bands.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically diagnosed with lung cancer
  • Stage I, II, or III
  • Eligible for chemotherapy with curative intent
  • 21 years of age or older
  • Approval to participate in study by treating oncologist or family physician

Exclusion Criteria:

  • Unstable cardiac disease
  • Untreated bone or brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01130714

Locations
United States, North Carolina
Leo Jenkins Cancer Center
Greenville, North Carolina, United States, 27834
Sponsors and Collaborators
East Carolina University
Investigators
Principal Investigator: Kristina H Karvinen, PhD East Carolina University
  More Information

No publications provided

Responsible Party: Kristina Karvinen, Assistant Professor, East Carolina University
ClinicalTrials.gov Identifier: NCT01130714     History of Changes
Other Study ID Numbers: UMCIRB 09-0725
Study First Received: January 6, 2010
Last Updated: July 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by East Carolina University:
inflammation
chemotherapy
lung cancer

Additional relevant MeSH terms:
Inflammation
Lung Neoplasms
Pathologic Processes
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 22, 2014